Details about Diego Useche

Access statistics for papers by Diego Useche.

Last updated 2024-03-08. Update your information in the RePEc Author Service.

Short-id: pus30

Working Papers

2022

1. Crowdfunding to overcome the immigrant entrepreneurs’ liability of outsidership: the role of internal social capital
   Post-Print, HAL View citations (1)
   See also Journal Article Crowdfunding to overcome the immigrant entrepreneurs’ liability of outsidership: the role of internal social capital, Small Business Economics, Springer (2022) View citations (5) (2022)

2021

2. Highly skilled and well connected: Migrant inventors in cross-border M&As
   Working Papers, HAL
   Also in Post-Print, HAL (2020) View citations (7)
   Working Papers, HAL (2021)
   See also Journal Article Highly skilled and well connected: Migrant inventors in cross-border M&As, Journal of International Business Studies, Palgrave Macmillan (2020) View citations (15) (2020)
3. Where do we go? VC firm heterogeneity and the exit routes of newly listed high-tech firms
   Post-Print, HAL View citations (1)
   See also Journal Article Where do we go? VC firm heterogeneity and the exit routes of newly listed high-tech firms, Small Business Economics, Springer (2021) View citations (1) (2021)

2020

4. Highly-skilled migrants and Cross-border M&A: Firm-level evidence
   Post-Print, HAL View citations (8)
   Also in Post-Print, HAL (2020) View citations (6)
   Post-Print, HAL (2017)
   Post-Print, HAL (2018)

2017

5. Empirical Economic Analysis of Orphan Drug Innovation
   Post-Print, HAL
   Also in Post-Print, HAL (2016)
   Post-Print, HAL (2016)
6. Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies
   NBER Working Papers, National Bureau of Economic Research, Inc
   Also in Post-Print, HAL (2015)
   Post-Print, HAL (2016)
   See also Chapter Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies, NBER Chapters, National Bureau of Economic Research, Inc (2018) (2018)
7. Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies. NBER working paper n° w24021
   Working Papers, HAL

2016

8. Empirical Economic Analysis of Orphan Drug Legislation Impact on Innovation
   Post-Print, HAL
   Also in Post-Print, HAL (2016)

2014

9. Are patents signals for the IPO market? An EU–US comparison for the software industry
   Post-Print, HAL View citations (23)
   See also Journal Article Are patents signals for the IPO market? An EU–US comparison for the software industry, Research Policy, Elsevier (2014) View citations (24) (2014)

Journal Articles

2022

1. Crowdfunding to overcome the immigrant entrepreneurs’ liability of outsidership: the role of internal social capital
   Small Business Economics, 2022, 59, (4), 1519-1540 View citations (5)
   See also Working Paper Crowdfunding to overcome the immigrant entrepreneurs’ liability of outsidership: the role of internal social capital, Post-Print (2022) View citations (1) (2022)

2021

2. Where do we go? VC firm heterogeneity and the exit routes of newly listed high-tech firms
   Small Business Economics, 2021, 57, (3), 1339-1359 View citations (1)
   See also Working Paper Where do we go? VC firm heterogeneity and the exit routes of newly listed high-tech firms, Post-Print (2021) View citations (1) (2021)

2020

3. Highly skilled and well connected: Migrant inventors in cross-border M&As
   Journal of International Business Studies, 2020, 51, (5), 737-763 View citations (15)
   See also Working Paper Highly skilled and well connected: Migrant inventors in cross-border M&As, Working Papers (2021) (2021)

2015

4. Patenting Behaviour and the Survival of Newly Listed European Software Firms
   Industry and Innovation, 2015, 22, (1), 37-58 View citations (4)

2014

5. Are patents signals for the IPO market? An EU–US comparison for the software industry
   Research Policy, 2014, 43, (8), 1299-1311 View citations (24)
   See also Working Paper Are patents signals for the IPO market? An EU–US comparison for the software industry, Post-Print (2014) View citations (23) (2014)

Chapters

2018

1. Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies
   A chapter in Economic Dimensions of Personalized and Precision Medicine, 2018, pp 305-334
   See also Working Paper Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies, National Bureau of Economic Research, Inc (2017) (2017)